Welcome to our dedicated page for Chemomab Therapeutics news (Ticker: CMMB), a resource for investors and traders seeking the latest updates and insights on Chemomab Therapeutics stock.
Chemomab Therapeutics Ltd. (CMMB) generates news primarily as a clinical-stage biotechnology company developing nebokitug, a monoclonal antibody targeting the soluble protein CCL24 in fibro-inflammatory diseases. Much of the company’s news flow centers on clinical data, regulatory interactions and scientific presentations related to primary sclerosing cholangitis (PSC), a rare and progressive liver disease with no effective medical therapy other than liver transplantation in advanced cases.
Investors and observers following Chemomab news can expect detailed updates on the Phase 2 SPRING trial of nebokitug in PSC, including results from the double-blind, placebo-controlled portion and the open label extension, where patients received nebokitug for up to 48 weeks. Press releases describe safety and tolerability findings, changes in biomarkers such as ELF score, PRO-C3 and liver stiffness measurements, and analyses in subgroups with moderate or advanced fibrosis. These reports often highlight biomarker patterns that are associated with PSC disease progression and transplant-free survival.
Chemomab’s news also covers regulatory milestones, such as outcomes of End-of-Phase 2 meetings with the FDA, alignment on a single Phase 3 registration trial design using a composite of clinically relevant events, and agreements on Chemistry, Manufacturing and Controls (CMC) and nonclinical toxicology requirements. Additional announcements address Orphan Drug and Fast Track designations for nebokitug, as well as the status of an open U.S. IND for systemic sclerosis.
Another recurring theme in Chemomab’s news releases is its scientific and investor outreach. The company reports oral and poster presentations at major liver and gastroenterology meetings, including Digestive Disease Week, BSG Live, AASLD The Liver Meeting and EASL congresses, where nebokitug data and CCL24-related mechanisms are discussed. Chemomab also announces participation in rare disease summits and global investment conferences, along with corporate updates tied to quarterly financial results, patent awards and capital markets activities such as at-the-market equity offerings or ADS ratio adjustments.
Readers of the CMMB news page on Stock Titan can use this stream of clinical, regulatory and corporate announcements to track Chemomab’s progress with nebokitug in PSC and other fibro-inflammatory indications, as well as to monitor key events that may influence the company’s development plans and regulatory trajectory.
Chemomab Therapeutics (Nasdaq: CMMB) presented significant findings regarding its lead candidate, CM-101, at recent conferences in Israel. Data indicated that CCL24 levels were elevated in patients with diffuse cutaneous systemic sclerosis (dcSSc), correlating with disease activity and poor prognosis. The company plans to initiate a Phase 2 trial for CM-101 later this year, aiming to target CCL24 to address unmet needs in systemic sclerosis, a serious autoimmune disease.
Chemomab Therapeutics, Ltd. (CMMB) reported its fourth quarter and full-year 2021 financial results, showcasing a cash position of $61.2 million compared to $11.8 million in 2020. R&D expenses rose to $2.4 million for Q4 and $6.3 million for the year, while G&A expenses increased to $2.6 million for Q4 and $6.0 million for the year. The net loss was $5.0 million for Q4, totaling $12.5 million for 2021. Significant clinical program revisions were announced, aimed at optimizing the development of CM-101, including expanded trials for PSC and SSc, with more data readouts expected over the next 24 months.
Chemomab Therapeutics (CMMB) will announce its fourth quarter and full year 2021 financial results on March 9, 2022. The company focuses on developing therapeutics for fibrotic and inflammatory diseases. A conference call will be held at 8:00 a.m. Eastern Time to discuss performance and upcoming events. Chemomab's key product, CM-101, is currently undergoing two Phase 2 trials with a third set to start in early 2022. This innovative approach targets the CCL24 protein, which is central to fibrosis and inflammation.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotechnology company, announced it will present at the Aegis Capital Corp. Virtual Conference on February 24, 2022, at 9:00 am ET. The company focuses on innovative therapeutics for fibrotic and inflammatory diseases, highlighting its monoclonal antibody CM-101, designed to block the soluble protein CCL24, which is linked to these conditions. CM-101 is currently undergoing two Phase 2 trials for primary sclerosing cholangitis and liver fibrosis, with a third trial in systemic sclerosis anticipated to start in early 2022.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) announced the appointment of Jack Lawler as Vice President of Global Clinical Development Operations, enhancing its clinical development leadership. Lawler brings over 22 years of experience in drug development, previously contributing to eight approved pharmaceuticals. Chemomab has also expanded its facilities in Tel Aviv to support anticipated growth. The company focuses on developing CM-101, a monoclonal antibody aimed at addressing serious fibrotic and inflammatory diseases, currently in two Phase 2 trials.
Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) announced participation in two key virtual events: the LifeSci Partners 11th Annual Corporate Access Event from January 5-7, 2022, featuring 1-on-1 meetings, and the H.C. Wainwright BioConnect Conference from January 10-13, 2022, offering an on-demand corporate overview webcast. Chemomab focuses on therapeutics for fibrotic and inflammatory diseases, with its lead candidate, CM-101, in Phase 2 trials targeting multiple severe conditions. For event registration and additional details, visit Chemomab's website.
Chemomab Therapeutics Ltd (Nasdaq: CMMB) has announced that CEO Dale R. Pfost will take on the role of Chairman, pending shareholder approval expected in February 2022. Stephen Squinto will step down from his role as Chairman and director on December 19, 2021. Dr. Pfost expressed excitement for the company's Phase 2 clinical programs in liver fibrosis and systemic sclerosis. Chemomab is developing CM-101, a monoclonal antibody targeting CCL24, currently undergoing clinical trials for severe fibrotic and inflammatory diseases.
Chemomab Therapeutics Ltd. (NASDAQ: CMMB) announced the appointment of David M. Weiner, MD, as Interim Chief Medical Officer, effective immediately. He replaces Dr. Arnon Aharon, who will remain for a 60-day transition period. Dr. Weiner brings over 25 years of biopharmaceutical experience and has held senior roles at various biotech companies. He aims to advance Chemomab's clinical programs, particularly for CM-101, a monoclonal antibody in Phase 2 trials targeting fibrotic diseases. The company acknowledges Dr. Aharon's contributions to its clinical advancements.
Chemomab Therapeutics (CMMB) announced its third-quarter financial results for 2021, revealing a significant cash position of $64.3 million, which is expected to fund operations until mid-2023. The company reported a net loss of $3.0 million, or ($0.01) per share, compared to a loss of $1.2 million in the previous year. Key updates included advancements in clinical trials for CM-101 aimed at treating fibrotic diseases and the appointment of Donald Marvin as CFO. Upcoming data readouts from ongoing Phase 2 trials are anticipated in 2022, suggesting potential growth for Chemomab's pipeline.
Chemomab Therapeutics (Nasdaq: CMMB) announced a poster presentation at The Liver Meeting 2021, showcasing its research on CCL24's role in Primary Sclerosing Cholangitis (PSC). The study highlights the high expression of CCL24 in PSC liver biopsies and the efficacy of the monoclonal antibody CM-101 in reducing liver injury in preclinical models. CM-101 is currently in Phase 2 trials targeting PSC and other fibrotic diseases. The company's advancements provide promising insights into potential treatment avenues.
FAQ
What is the current stock price of Chemomab Therapeutics (CMMB)?
What is the market cap of Chemomab Therapeutics (CMMB)?
